---
title: "Sermorelin Tablets: Why Oral and Sublingual Forms Are a Hard Sell"
canonical_url: https://peptidelibrary.app/blog/sermorelin-tablets
description: "Sermorelin has an 11-minute half-life and 29 residues. Both of those numbers argue against a tablet."
updated: 2026-08-30
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Sermorelin Tablets: Why Oral and Sublingual Forms Are a Hard Sell

Sermorelin has an 11-minute half-life and 29 residues. Both of those numbers argue against a tablet.

**Sermorelin is sold as tablets, capsules and sublingual troches, and two numbers make that a difficult proposition. **It is 29 amino acids long, and its half-life is roughly 11 to 12 minutes.

Each of those creates a separate problem for an oral product.

## Problem one: length

At 29 residues, sermorelin is a polypeptide rather than a short peptide. That length is a liability in the gut — more residues means more cleavage sites for trypsin, chymotrypsin and brush-border peptidases, and a larger molecule crosses the intestinal wall less readily.

| **Compound** | **Length** | **Oral prospects** |
| --- | --- | --- |
| GHK-Cu, KPV | 3 | Better — small and robust |
| BPC-157 | 15 | Debated; see the capsules guide |
| Sermorelin | 29 | Poor |
| Semaglutide | 31 backbone | Only with a purpose-built enhancer |

**Semaglutide is the instructive comparison. **At a similar length, an oral form required co-formulation with a dedicated absorption enhancer, gastric-site absorption, strict dosing conditions and roughly hundredfold dose inflation — plus a full clinical programme. See the [oral semaglutide guide](https://peptidelibrary.app/blog/oral-semaglutide).

## Problem two: half-life

Sermorelin is cleared in about 11 to 12 minutes. That is extremely short, and it is central to how the compound is supposed to work — a brief pulse triggering a pulse of growth hormone release.

> **A short half-life makes slow absorption self-defeating. **Oral or sublingual absorption is gradual and incomplete. A compound cleared in minutes, absorbed slowly over a longer period, may never reach the concentration needed to trigger the pituitary response at all — the drug is being removed as fast as it arrives.

## The sublingual argument

Sublingual and buccal delivery bypasses the gut and first-pass hepatic metabolism, which is a genuine advantage. It works well for small, lipophilic molecules — nitroglycerin being the classic example.

- **The oral mucosa is thin and well perfused, **which is the basis of the approach.
- **It is still a barrier **to large, hydrophilic molecules, and a 29-residue peptide is both.
- **Contact time is limited **by swallowing — anything swallowed enters the gut and faces the original problem.
- **No published pharmacokinetic data **establishes sublingual sermorelin bioavailability in humans.
- **No approved sublingual peptide of this size exists, **which is informative.

> **The absence of pharmacokinetic data is the crux. **Nothing published shows what plasma concentration a sublingual sermorelin product achieves, or whether it triggers growth hormone release at all. Without that, "sublingual sermorelin" is a formulation claim rather than a demonstrated route.

## What would demonstrate it works

Sermorelin has a convenient property for testing: its effect is measurable. Unlike compounds with subjective endpoints, a GHRH analogue either provokes growth hormone release or it does not.

1. **Serial growth hormone measurements **after an oral or sublingual dose.
2. **Comparison against the injectable route **in the same participants.
3. **IGF-1 over weeks, **as the downstream marker.
4. **A dose-response relationship **by the oral route.

**None of these studies has been published for oral sermorelin. **For contrast, a 2026 phase 3 study of once-weekly somatrogon in adults with growth hormone deficiency shows what a properly measured GH-axis intervention looks like — diagnosed population, randomisation, defined endpoints.

## The regulatory position

Sermorelin was approved in the US as Geref and was withdrawn from the market for commercial reasons rather than a safety finding. It is not currently an approved product, and "formerly approved" is routinely shortened to "FDA approved" in marketing.

**No oral or sublingual sermorelin product has ever been approved in any form. **The approved product was an injection.

## If considering an oral product

| **Claim** | **What to ask** |
| --- | --- |
| "Sublingual absorption" | What bioavailability, measured how? |
| "Enhanced delivery" | By what mechanism, with what data? |
| "Equivalent to injection" | Compared in whom, measuring what? |
| "Pharmaceutical grade" | Against which monograph? |
| "FDA approved" | Formerly approved as an injection; not this product |

See the [sermorelin dosage guide](https://peptidelibrary.app/blog/sermorelin-dosage), [sermorelin before and after](https://peptidelibrary.app/blog/sermorelin-before-and-after), the [oral peptides guide](https://peptidelibrary.app/blog/oral-peptides) and the [licensed vs certified guide](https://peptidelibrary.app/blog/licensed-vs-certified-peptides).

> **Research and educational use only. **Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

## Sources

- [Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study](https://pubmed.ncbi.nlm.nih.gov/41879875/)
- [A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules](https://pubmed.ncbi.nlm.nih.gov/42256195/)
